• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Safeguard Scientifics Adds Michael J. Pellini, MD to Life Sciences Group

Posted on: Monday, 29 January 2007, 09:01 CST

Safeguard Scientifics, Inc. (NYSE:SFE), which builds value in high-growth, revenue-stage technology and life sciences companies, today announced that Michael J. Pellini, MD, joined Safeguard's Life Sciences Group as an Executive in Residence. Dr. Pellini will work alongside senior members of the Life Sciences team to explore new market opportunities, evaluate deals and provide counsel and support to Safeguard and its partner companies on strategic and business development opportunities.

"Mike's extensive experience in diagnostics and specialty pharma provides additional competencies for Safeguard to pursue its strategic focus in Life Sciences while also providing its partner companies with an extensive range of strategic and business expertise," said James A. Datin, Executive Vice President and Managing Director of the Life Sciences Group. "Mike's operational experience, analytical abilities and industry knowledge will be instrumental in extending Safeguard's reach to current and future life sciences partner companies. We are pleased that Mike has joined Safeguard and look forward to his contributions to the team."

Prior to joining Safeguard, Dr. Pellini was Chief Operating Officer at Lakewood Pathology Associates, Inc., a national anatomical pathology company that provides comprehensive molecular and pathology services tailored toward the outpatient needs of surgical sub-specialists. Prior to that, Dr. Pellini was an Entrepreneur in Residence at BioAdvance, where he was responsible for reviewing and evaluating seed stage investment proposals. From 1999 to 2004, Dr. Pellini served as President and Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm which was acquired by SeraCare Life Sciences, Inc. in 2004.

Dr. Pellini is a native of the greater Philadelphia region. He received his medical degree from Jefferson Medical College of Thomas Jefferson University and his MBA from Drexel University. Dr. Pellini trained as a primary care physician in the Thomas Jefferson University Health System. Before attending medical school, he worked in the investment banking industry in both Philadelphia and Sydney, Australia. Dr. Pellini serves on the Board of Directors for Cira Discovery Sciences, Inc., the Executive Committee of the Board of Trustees for the Coriell Institute of Medical Research, the Alumni Association Executive Committee for Jefferson Medical College, the Technology Council of Boston College, and the Editorial Board for the journal Biotechnology Healthcare.

About Safeguard

Safeguard Scientifics, Inc. (NYSE:SFE) builds value in high-growth, revenue-stage technology and life sciences businesses. We provide growth capital as well as a range of strategic, operational and management resources to our partner companies. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. www.safeguard.com.

Except for the historical information and discussions contained herein, statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements are subject to risks and uncertainties. These forward-looking statements that could cause actual results to differ materially, include, among others, managing rapidly changing technologies, limited access to capital, competition, the ability to attract and retain qualified employees, the ability to execute our strategy, the uncertainty of the future performance of our companies, acquisitions and dispositions of companies, the inability to manage growth, compliance with government regulations and legal liabilities, additional financing requirements, labor disputes, the effect of economic conditions in the business sectors in which our companies operate, and other uncertainties described in the Company's filings with the Securities and Exchange Commission. Many of these factors are beyond our ability to predict or control. In addition, as a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release.

Source: Business Wire

More News in this Category